Treanda(Teva/Mundipharma)success in NHL study

Treanda/Levact(bendamustine) from Teva/Mundipharma/Napp combined with Rituxan/MabThera outperformed the current standard of care in treating Non-Hodgkin's Lymphoma (NHL).In the trial, which included more than 500 patients, Treanda slowed NHL growth for 55 months, compared with just 35 months in those patients taking the standard four-drug treatment. After 32 months, 40 percent of Treanda patients experienced full remission, while 31 percent went into remission on the four drug regimen. Treanda was also associated with less hair loss and fewer infections